Novartis Joins Harvard, Dana-Farber to Develop Cancer Therapy Systems
March 20 2018 - 3:17AM
Dow Jones News
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Tuesday that it is teaming up with
scientists from the Wyss Institute for Biologically Inspired
Engineering at Harvard University and the Dana-Farber Cancer
Institute to develop cancer therapy systems.
The Swiss pharmaceutical company has reached a collaboration and
licensing agreement to develop biomaterial systems for its
portfolio of immuno-oncology therapies.
The aim of the licensed systems is to overcome barriers that
have hampered traditional cancer vaccines, it said.
Novartis will collaborate with the Wyss Institute to advance
development of biomaterial systems that researchers have engineered
to provide sustained delivery of immunotherapies and target
specific types of cancer.
The technologies licensed under the agreement are owned or
co-owned by Harvard University, Dana-Farber and the University of
Michigan, it said.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
March 20, 2018 03:02 ET (07:02 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024